Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study

Patruno, Cataldo; Fabbrocini, Gabriella; Longo, Giuseppe; Argenziano, Giuseppe; Ferrucci, Silvia; Stingeni, Luca; Peris, Ketty; Ortoncelli, Michela; Offidani, Annamaria; Amoruso, Giuseppe Fabrizio; Talamonti, Marina; Girolomoni, Giampiero; Grieco, Teresa; Iannone, Michela; Nettis, Eustachio; Foti, Caterina; Rongioletti, Franco; Corazza, Monica; Veneri, Michele Delli; Napolitano, Maddalena; Angileri, Luisa; Bianchelli, Tommaso; Borghi, Alessandro; Calabrese, Giulia; Chello, Camilla; Bello, Giacomo Dal; Dastoli, Stefano; Ferrillo, Maria; Galluzzo, Marco; Gori, Niccolò; Hansel, Katharina; Macchia, Luigi; Piras, Viviana; Provenzano, Eugenio; Ribero, Simone; Romanelli, Marco; Romita, Paolo

doi:10.1007/s40257-021-00597-5

Cited by 49 publications

(41 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, older patients and those with a longer disease duration were found to have better efficacy with dupilumab. Similar to the results of an Italian real-world study in which elderly patients (≥65 years) with severe AD treated with dupilumab showed significant and persistent improvement in EASI, Pruritus-NRS, Sleep-NRS, and DLQI at 16 weeks and 52 weeks compared with baseline ( 25 ). Identifying this characteristic will lead to more informed drug choices in the future.…”

Section: Discussionsupporting

confidence: 79%

Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study

Zhou

Peng

et al. 2022

Front. Med.

View full text Add to dashboard Cite

BackgroundAtopic dermatitis (AD) is a common skin disease, but treatment of this disease has been challenging. Dupilumab is a new biological agent for AD that has been proven to be safe and effective in clinical trials. Although dupilumab was approved for listing in China in June 2020, real-world data about the application of dupilumab in China are lacking. This study aimed to collect and analyze real-world data on dupilumab among Chinese AD patients.MethodsDemographic and clinical data for 116 AD patients receiving dupilumab treatment were reviewed. The Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), Numerical Rating Scale (NRS), Patient Oriented Eczema Measure (POEM), and Dermatology Quality of Life Index (DLQI) of patients were evaluated every 2 weeks from baseline to 16 weeks of treatment. Any adverse events during treatment were recorded.ResultsAmong the 116 patients in this study, baseline levels of IgE, eosinophils, and LDH were elevated in 62.79% (n = 86), 45.30% (n = 86), and 54.20% of patients (n = 48), respectively. The SCORAD index and POEM, DLQI, and NRS scores were significantly improved in all patients at 2 weeks (p < 0.0001), 4 weeks (p < 0.01), and 16 weeks (p < 0.001). EASI scores also improved significantly in all patients at 2 weeks (p < 0.01), 4 weeks (> 0.05), and 16 weeks (p < 0.01). However, 11 patients (9.48%) had no response. IgE and LDH levels (p > 0.05), Eosinophil counts (p < 0.01) in blood increased temporarily in the first 4 weeks and then decreased and stabilized during dupilumab treatment. Conjunctivitis was the most common adverse event (2.59%) among the patients. We found that the curative efficacy of dupilumab at 4th weeks was related to the patient’s age and course of disease. Nevertheless, there is no relationship between levels of eosinophils, IgE, LDH and the therapeutic efficacy of dupilumab.ConclusionThe real-world data in China showed that dupilumab can effectively treat AD and is well tolerated with a low incidence of adverse events.

show abstract

Section: Discussionsupporting

confidence: 79%

Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study

Zhou

Peng

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Real-world evidence of the effectiveness and safety of dupilumab for atopic dermatitis Accumulating real-world evidence has ensured the effectiveness and tolerable safety of dupilumab both in the short term and in the long term. The articles searched in PubMed and Google Scholar are shown in Table 1 (Ariëns et al, 2020, Ariëns et al, 2021, Faiz et al, 2019, Fargnoli et al, 2020, Fargnoli et al, 2019, Jang et al, 2020, Jo et al, 2020a, Kreeshan et al, 2021, Matsutani et al, 2020, Nettis et al, 2020b, Nettis et al, 2020c, Olesen et al, 2019, Patruno et al, 2021a, Patruno et al, 2021b, Quint et al, 2020, Ribero et al, 2020, Sears et al, 2020, Tauber et al, 2019, Uchida et al, 2021, Uchida et al, 2019. Patruno et al reported the effectiveness and safety of dupilumab in elderly patients with AD in real life (Patruno et al, 2021a, Patruno et al, 2021b.…”

Section: Effectiveness and Safety Of Dupilumab For Atopic Dermatitis In The Real Worldmentioning

confidence: 99%

“…The articles searched in PubMed and Google Scholar are shown in Table 1 (Ariëns et al, 2020, Ariëns et al, 2021, Faiz et al, 2019, Fargnoli et al, 2020, Fargnoli et al, 2019, Jang et al, 2020, Jo et al, 2020a, Kreeshan et al, 2021, Matsutani et al, 2020, Nettis et al, 2020b, Nettis et al, 2020c, Olesen et al, 2019, Patruno et al, 2021a, Patruno et al, 2021b, Quint et al, 2020, Ribero et al, 2020, Sears et al, 2020, Tauber et al, 2019, Uchida et al, 2021, Uchida et al, 2019. Patruno et al reported the effectiveness and safety of dupilumab in elderly patients with AD in real life (Patruno et al, 2021a, Patruno et al, 2021b. Halling et al reported a systematic review and meta-analysis of real-world data on the efficacy and safety of dupilumab in patients with AD (Halling et al, 2021).…”

Section: Effectiveness and Safety Of Dupilumab For Atopic Dermatitis In The Real Worldmentioning

confidence: 99%

“…The articles searched in PubMed and Google Scholar are shown in Table 1 ( Ariëns et al., 2021 , 2020 ; Armario-Hita et al., 2019 ; Faiz et al., 2019 ; Fargnoli et al, 2020 , 2019 ; Ferrucci et al., 2020 ; Jang et al., 2020 ; Jo et al., 2020a , 2020b ; Kim et al., 2020 ; Kreeshan et al., 2021 ; Matsutani et al., 2020 ; Nettis et al., 2020b , 2020c ; Olesen et al., 2019 ; Patruno et al., 2021a , 2021b ; Quint et al., 2020 ; Ribero et al., 2020 ; Sears et al., 2021 ; Tauber et al., 2019 ; Tavecchio et al., 2020 ; Uchida et al., 2021 , 2019 ; Wang et al., 2020 ; Yamauchi et al., 2021 ). Patruno et al. (2021a , 2021b) reported the effectiveness and safety of dupilumab in elderly patients with AD in real life.…”

Section: Effectiveness and Safety Of Dupilumab For Ad In The Real Worldmentioning

confidence: 99%

“…A total of 61 patients (22.51%) reported adverse events, conjunctivitis and flushing being the most frequent adverse events. Patruno et al (2021a) Italy 52 105 ND Data of elderly patients (aged ≥ 65 years) with severe (EASI ≥24) AD treated with dupilumab were studied. The mean EASI percentage improvement from baseline was 56.0%, 83.9%, and 87.2% after 16, 32, and 52 weeks, respectively.…”

Section: Effectiveness and Safety Of Dupilumab For Ad In The Real Worldmentioning

confidence: 99%

See 2 more Smart Citations

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

Kamata

Tada

2021

JID Innovations

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis

van der Rijst,

Kamphuis,

Schuttelaar

et al. 2024

JAMA Dermatol

View full text Add to dashboard Cite

ImportanceDupilumab, methotrexate (MTX), and cyclosporine A (CsA) are valuable treatment options for pediatric patients with refractory moderate to severe atopic dermatitis (AD). Yet, comparative data on these treatments in pediatric patients are scarce.ObjectiveTo evaluate drug survival of dupilumab, MTX, and CsA, and identify associated predictors in a multicenter daily practice cohort study of pediatric patients with AD.Design, Setting, and ParticipantsThis multicenter daily practice cohort study included patients with AD aged 2 to 17 years treated with dupilumab, MTX, and/or CsA in 5 tertiary centers in the Netherlands between 2013 and 2023. Data were extracted from the prospective BioDay and TREAT Netherlands registries and electronic medical records.ExposuresDupilumab, MTX, CsA.Main Outcomes and MeasuresDrug survival was analyzed using Cox proportional hazard regression models. Univariable and multivariable Cox regression analyses were conducted to identify variables associated with drug discontinuation.ResultsA total of 502 treatment episodes in 362 unique patients were included, comprising 192 dupilumab episodes, 94 MTX episodes, and 216 CsA episodes. Overall, the mean (SD) age at treatment initiation was 12.9 (3.8) years, and 272 treatment episodes (54.2%) in female patients. The 1-year, 2-year, and 3-year overall drug survival rates, respectively, were 84.1%, 72.3%, and 62.0% for dupilumab; 60.7%, 39.3%, and 25.3% for MTX; and 43.9%, 21.5%, and 10.4% for CsA. Ineffectiveness was the most frequent reason for drug discontinuation, accounting for 178 episodes (35.5%), mostly in patients treated with CsA, followed by adverse effects in 94 patients (18.7%). Treatment with MTX and treatment with CsA were independently associated with a higher risk for drug discontinuation due to ineffectiveness (hazard ratio [HR], 4.45 [95% CI, 2.38-8.34] and HR, 10.88 [95% CI, 6.23-19.02], respectively) and adverse effects (HR, 4.39 [95% CI, 2.05-9.39] and HR, 3.83 [95% CI, 1.85-7.92], respectively) compared to treatment with dupilumab. Patients aged 12 to 17 years starting systemic treatment were independently associated with a higher risk for drug discontinuation due to ineffectiveness (HR, 1.55 [95% CI, 1.10-2.20]) and adverse effects (HR, 2.39 [95% CI, 1.33-4.30]).Conclusions and RelevanceThis multicenter daily practice cohort study demonstrated a superior 1-year, 2-year, and 3-year overall drug survival for dupilumab, followed by MTX, with the lowest rates observed for CsA in pediatric patients with AD. This study also identified characteristics associated with discontinuation. These results provide insight into drug survival resulting from the effectiveness, safety, and tolerability of these systemic treatments in pediatric patients with AD and contribute to the optimization of patient outcomes.

show abstract

Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study

Cited by 49 publications

References 10 publications

Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study

Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis

Contact Info

Product

Resources

About